S-8

As filed with the Securities and Exchange Commission on August 4, 2025

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

____________________________________________

Medifast, Inc.

(Exact name of registrant as specified in its charter)

____________________________________________

Delaware

(State or other jurisdiction of incorporation or organization)

13-3714405

(I.R.S. Employer Identification Number)

____________________________________________

100 International Drive

18th Floor

Baltimore, Maryland 21012

(Address of Principal Executive Offices)

____________________________________________

Medifast, Inc. Amended and Restated 2012 Share Incentive Plan

(Full title of the plan)

____________________________________________

Jason L. Groves, Esq.

Chief Legal Officer & Corporate Secretary

Medifast, Inc.

100 International Drive

18th Floor

Baltimore, Maryland 21012

Tel: (410) 581-8042

Copy to:

Bryan Brown, Esq.

Jones Day

717 Texas

Suite 3300

Houston, Texas 77002

Tel: (832) 239-3939

(Name, address and telephone number (including area code) of agent for service)

____________________________________________

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐

Non-accelerated filer ☐

Accelerated filer ☒

Smaller reporting company ☐

Emerging Growth Company ☐

Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiodforcomplyingwithany new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the SecuritiesAct.☐

EXPLANATORY NOTE

This Registration Statement is filed by Medifast, Inc., a Delaware corporation (the “Registrant”), pursuant to General Instruction E to Form S-8 to register an additional 550,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), which may be awarded under the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the “Plan”). On June 18, 2025, the Registrant’s stockholders approved the amendment and restatement of the Plan that increased by 550,000 the number of shares of Common Stock with respect to which the Registrant may make awards under the Plan.

The additional shares of Common Stock registered hereby pursuant to the Plan are of the same class as other securities relating to the Plan for which registration statements on Form S-8 (Nos. 333-282913, 333-187974, and 333-218243 are effective (the “Prior Registration Statements”)). The contents of the Prior Registration Statements are incorporated herein by reference and made a part hereof except to the extent supplemented, amended or superseded by the information set forth herein.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants in the Plan, as required by Rule 428 promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act. Such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in the Registration Statement shall constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents previously filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

aThe Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Commission on February 18, 2025;

bThe Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, as filed with the Commission on April 28, 2025 and August 4, 2025, respectively;

cThe Registrant’s Current Report on Form 8-K, as filed with the Commission on June 20, 2025; and

dThe description of the Common Stock contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Commission on February 26, 2021, including any amendments or reports filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining

unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein.

Any statement contained herein, or in a document incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

Section 102 of the Delaware General Corporation Law (the “DGCL”) permits a corporation to eliminate the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except (i) in cases where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or a knowing violation of the law, (ii) in cases where the director willfully or negligently authorized the unlawful payment of a dividend or approved an unlawful stock redemption or repurchase or obtained an improper personal benefit or, (iii) with respect to officers, in any action by or in the right of the Registrant. The Registrant’s Restated and Amended Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and By-laws, (the “By-laws”), each contain a provision that eliminates directors’ personal liability as set forth above.

The Certificate of Incorporation and the By-laws provide in effect that the Registrant shall indemnify its directors and officers to the full extent permitted by the DGCL, Section 145 of the DGCL provides that a corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Such indemnification may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. A Delaware corporation is permitted to indemnify directors, officers, employees and other agents of such corporation in an action by or in the right of the corporation under the same conditions, except that no indemnification is permitted without judicial approval if the person to be indemnified has been adjudged to be liable to the corporation. Where a director, officer, employee or agent of the corporation is successful on the merits or otherwise in the defense of any action, suit or proceeding referred to above or in defense of any claim, issue or matter therein, the corporation must indemnify such person against the expenses (including attorneys’ fees) which he or she actually and reasonably incurred in connection therewith.

The Registrant maintains policies insuring its officers and directors against certain civil liabilities, including liabilities under the Securities Act.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

Exhibit Number	Description of Documents
4.1	Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (incorporated by reference from Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 20, 2025)
5.1	Opinion of Jones Day *
23.1	Consent of RSM US LLP *
23.2	Consent of Jones Day (included in Exhibit 5.1)
24.1	Power of Attorney (included on signature page hereto)
107	Calculation of Filing Fee Table *
* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Baltimore, State of Maryland, on August 4, 2025.

Medifast, Inc.

By:     /s/ DANIEL R. CHARD

Daniel R. Chard

Chairman & Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, Daniel R. Chard and Jason L. Groves, Esq. and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

Name	Title	Date
/s/ JEFFREY J. BROWN	Lead Director	August 4, 2025
Jeffrey J. Brown
/s/ DANIEL R. CHARD	Chairman and Chief Executive Officer	August 4, 2025
Daniel R. Chard
/s/ ELIZABETH A. GEARY	Director	August 4, 2025
Elizabeth A. Geary
/s/ MICHAEL A. HOER	Director	August 4, 2025
Michael A. Hoer
/s/ JONATHAN B. MACKENZIE	Vice President Finance and Chief Accounting Officer	August 4, 2025
Jonathan B. MacKenzie
/s/ JAMES P. MALONEY	Chief Financial Officer	August 4, 2025
James P. Maloney
/s/ SCOTT SCHLACKMAN	Director	August 4, 2025
Scott Schlackman
/s/ ANDREA B. THOMAS	Director	August 4, 2025
Andrea B. Thomas
/s/ MING XIAN	Director	August 4, 2025
Ming Xian

EX-5.1

Exhibit 5.1

Jones Day

717 Texas

Suite 3300

Houston, Texas 77002

August 4, 2025

Medifast, Inc.

100 International Drive, 18th Floor

Baltimore, Maryland 21012

Re: Registration Statement on Form S-8 filed by Medifast, Inc.

Ladies and Gentlemen:

We have acted as counsel for Medifast, Inc., a Delaware corporation (the “Company”), in connection with the registration of 550,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, that may be issued or delivered and sold pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the “Plan”). In connection with the opinion expressed herein, we have examined such documents, records and matters of law as we have deemed relevant or necessary for purposes of such opinion. Based on the foregoing, and subject to the further limitations, qualifications and assumptions set forth herein, we are of the opinion that the Shares that may be issued or delivered and sold pursuant to the Plan and the authorized forms of applicable award agreements thereunder (the “Award Agreements”) will be, when issued or delivered and sold in accordance with the Plan and the Award Agreements, validly issued, fully paid and nonassessable, provided that the consideration for the Shares is at least equal to the stated par value thereof.

The opinion expressed herein is limited to the General Corporation Law of the State of Delaware, as currently in effect, and we express no opinion as to the effect of the laws of any other jurisdiction on the opinion expressed herein. In addition, we have assumed that the resolutions authorizing the Company to issue or deliver and sell the Shares pursuant to the Plan and the Award Agreements will be in full force and effect at all times at which such Shares are issued or delivered or sold by the Company, and that the Company will take no action inconsistent with such resolutions. In rendering the opinion above, we have assumed that each award under the Plan will be approved by the Board of Directors of the Company or an authorized committee thereof.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement on Form S-8 filed by the Company to effect registration of the Shares under the Securities Act of 1933 (the “Act”). In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

Sincerely yours,

/s/ Jones Day

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference inthis Registration Statement on Form S-8 of Medifast, Inc. of our reports dated February 18, 2025, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting of Medifast, Inc., appearing inthe Annual Report on Form 10-K of Medifast, Inc. for the year ended December 31, 2024.

/s/ RSM US LLP

Baltimore, Maryland

August 4, 2025

EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Medifast, Inc.

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount to be registered (1)	Proposed Maximum Offering Price Per Unit ($)(2)	Maximum Aggregate Offering Price ($)(2)	Fee Rate	Amount of Registration Fee ($)
Equity	Common Stock, par value $0.001 per share	457(h)	550,000	14.18	7,799,000	0.00015310	1,194.03
Total Offering Amounts					7,799,000		1,194.03
Total Fee Offsets							0.00
Net Fee Due							1,194.03

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers such indeterminable number of additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), that become issuable under the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan, as amended and restated (the “Amended and Restated 2012 Plan”), by reason of any stock splits, stock dividends, recapitalization or similar transactions. The amount to be registered represents 550,000 additional shares of Common Stock that are available for grant under the Amended and Restated 2012 Plan, as amended and approved by the Registrant’s stockholders at its annual meeting on June 18, 2025.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Common Stock as reported on the New York Stock Exchange on July 30, 2025, which date is within five business days prior to filing this Registration Statement in accordance with Rule 457(c) of the Securities Act.

XML

Submission	Aug. 04, 2025
Submission [Line Items]
Central Index Key	0000910329
Registrant Name	Medifast, Inc.
Form Type	S-8
Submission Type	S-8
Fee Exhibit Type	EX-FILING FEES

XML

Offerings - Offering: 1

Aug. 04, 2025

USD ($)

shares

$ / shares

Rate

Offering:

Fee Previously Paid

false

Other Rule

true

Security Type

Equity

Security Class Title

Common Stock, par value $0.001 per share

Amount Registered | shares

550,000

Proposed Maximum Offering Price per Unit | $ / shares

14.18

Maximum Aggregate Offering Price

$ 7,799,000

Fee Rate | Rate

0.01531%

Amount of Registration Fee

$ 1,194.03

Offering Note

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers such indeterminable number of additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), that become issuable under the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan, as amended and restated (the “Amended and Restated 2012 Plan”), by reason of any stock splits, stock dividends, recapitalization or similar transactions. The amount to be registered represents 550,000 additional shares of Common Stock that are available for grant under the Amended and Restated 2012 Plan, as amended and approved by the Registrant’s stockholders at its annual meeting on June 18, 2025.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Common Stock as reported on the New York Stock Exchange on July 30, 2025, which date is within five business days prior to filing this Registration Statement in accordance with Rule 457(c) of the Securities Act.

XML

Fees Summary	Aug. 04, 2025 USD ($)
Fees Summary [Line Items]
Total Offering	$ 7,799,000
Total Fee Amount	1,194.03
Total Offset Amount	0.00
Net Fee	$ 1,194.03